DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function
Platelet Aggregation During Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Platelet Aggregation During Acute Myocardial Infarction focused on measuring diabetes mellitus, platelet function testing, acute coronary syndromes, saxagliptin, sitagliptin, dpp-4 inhibitors
Eligibility Criteria
Inclusion Criteria:
- previous diagnosis of type 2 diabetes mellitus,with treatment including insulin and/or oral antidiabetic agent;
- subjects without previous diagnosis of diabetes,but HbA1c admission >= 6,5% during current hospital-stay
- AMI with or without ST-elevation;
- use of double antiplatelet therapy;
- signed informed consent term
Exclusion Criteria:
- GFR <30 ml/min;
- use of DPP4 inhibitors or glucagon- like peptide-1(GLP1) analogue in the past 6 months;
- use of strong inhibitors of cytochrome P450(CYP3A4/5) ou glucocorticoids;
- severe systemic decompensation requiring insulin infusion;
- Killip classification of myocardial infarction grade >2;
- previous history of pancreatitis
Sites / Locations
- Heart Institute(InCor)-Acute Coronary Care Unit
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
treatment: DPP4 -i
control
Use of DPP4-i : sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD) OR saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)
placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD